Background/Purpose: Whether the length of stent affects stent-related symptoms after urological procedures remains controversial. We aimed to evaluate the predictive factors for stent-related urinary tract symptoms after uncomplicated ureteroscopic lithotripsy (URSL). Methods: We prospectively recruited a total of 59 patients who underwent URSL and 6-Fr double-J ureteral stent placement. The demographic and perioperative data and stent characteristics, including the length (22, 24 or 26 cm), position of proximal end (upper calyx or pelvis), position of distal end (crossing midline or not), and configurations of both ends (complete or incomplete curl) were recorded. All patients completed a self-administered questionnaire to evaluate the stent-related urinary symptoms, bladder pain, flank pain and hematuria 1 week after the procedure. All variables were analyzed by a proportional odds logistic regression model. Results: Twenty-two male (37.3%) and 37 (62.7%) female patients were enrolled in this study. Their mean age was 53.7 ± 12.9 years. The mean body height was 161.9 ± 7.9 cm (range, 145.9-178 cm). In multivariate analysis, the 26-cm stent was independently associated with the severity of frequency, urgency, and nocturia symptoms. Crossing the midline of the distal end was significantly associated with urge incontinence. The 24-cm and 26-cm stents were both very strongly associated with the severity of hematuria. Crossing the midline of the distal end was significantly associated with bladder pain. Conclusion: The length of stent and crossing the midline of the distal end were significantly associated with stent-related symptoms after URSL. Selection of the proper length of double-J stent is the most important factor in minimizing stent-related symptoms.
which have a negative impact on the quality of life. [1] [2] [3] The most common complaints after ureteroscopic stone lithotripsy (URSL) are associated with stents left in place postoperatively. The exact pathophysiology of stent-related symptoms remains unknown. Bladder symptoms are thought to be a result of mucosal irritation of the nerve located in the submucosa in the bladder trigone. Flank pain is thought to be due to reflux of urine from the bladder to the kidney, especially during micturition. The relationship between stent characteristics such as diameter, length, material, softness, position, and curl completeness and the stent-related symptoms have been investigated by several researchers. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] However, the exact factors that affect the stent-related symptoms remain unclear. In the present study, we prospectively collected 59 patients who underwent uncomplicated URSL with the placement of a double-J stent. We evaluated the urinary symptoms by a specific questionnaire and clarified the predictive factors for stent-related symptoms by multivariate analysis.
Patients and Methods
After obtaining informed consent, we prospectively evaluated 59 eligible patients with ureteral stones diagnosed by intravenous urography who underwent URSL in a single institute from August 2007 to April 2008. All patients were anesthetized intravenously with propofol. The stones were disintegrated by a semirigid 6.5-Fr ureteroscope (Richard Wolf USA, Vernon Hills, IL, USA) with a holmium-YAG laser. One of three lengths of 6-Fr double-J ureteral stent was inserted at the end of the operation (22 cm, 24 cm or 26 cm). All of the stents were made of polyurethane (Cook Ireland Ltd., Limerick, Ireland). The double-J stent was inserted retrogradely via a guidewire under direct ureteroscopic vision at the end of the procedure. We chose the stent length randomly. The indwelled Foley catheter was removed and the patient was discharged on the next day after URSL. All procedures were completed without complications (no ureteral injury or intraoperative stone migration to the kidneys). After the operation, cephalexin (500 mg, 4 times daily) and acetaminophen (500 mg, 4 times daily) were prescribed for 4 days. The exclusion criteria included: (1) concomitant renal stones or residual stones on the postoperative plain film (KUB) and renal ultrasonography; (2) pre-procedural urological diseases that caused lower urinary tract symptoms or bladder pain, including prostate disease (benign prostate hypertrophy, chronic prostatitis, and prostate cancer), overactive bladder, interstitial cystitis, painful bladder syndrome, urinary incontinence, and urinary tract infection; (3) long-term medications with α-blockers, anticholinergics or analgesics; and (4) the presence of procedureassociated complications such as fragment migration to the kidneys, ureteral injury, urinary tract infection, or stent malposition. One week after URSL, a plain (KUB) film and renal ultrasonography images were obtained at the clinic for all the patients to confirm the stent position and the presence of residual stones. All films were reviewed by a single urologist. In addition to the length of stent, four characteristics on the image were recorded: (1) the position of the proximal curl (in the upper pole or the renal pelvis); (2) the position of the distal curl (crossing the midline or not); (3) the completeness of the proximal curl; and (4) the completeness of the distal curl. At the same time, all patients were asked to complete the self-administered questionnaire in outpatient clinics to assess their symptoms in the period of stenting. The investigated symptoms included frequency, urgency, nocturia, urge incontinence, hematuria, flank pain, and bladder pain (see Appendix) . To assess the severity of each symptom, the questions were adapted from the questionnaire of the International Prostate Symptoms Score (IPSS). The severity of flank and bladder pain was evaluated with a pain score, of 0-5, with 0 = pain, and 5 = the worst pain ever experienced.
Statistical analysis was performed with SAS version 9.1.3 (SAS Institute Inc., Cary, NC, USA). Two-tailed p ≤ 0.05 was considered statistically significant. Continuous data were expressed as mean ± standard deviation unless otherwise specified. Percentages were calculated for categorical variables. Descriptive analysis of all available variables was performed. In multivariate analysis, the commonly used proportional odds logistic regression model was fitted to the observed polychotomous categorical response with ordered categories. Each symptom question was originally scored as 0 for "no symptom" and 1-5 to indicate the chance of having the symptom, or its severity from low to high (Appendix) . We re-classified the 0-5 symptom scores into three ordered grading categories as the polychotomous response variable: 1 = no symptom (for symptom score = 0); 2 = mild symptom (for symptom scores = 1 or 2); and 3 = severe symptom (for symptom scores = 3-5). Basic model-fitting techniques for (1) variable selection, (2) goodness-of-fit (GOF) assessment, and (3) regression diagnostics (e.g. test of the proportional odds assumption, residual analysis, detection of influential cases, and check for multicollinearity) were used in our regression analyses to ensure the quality of the results. In the stepwise variable selection, both the significant level for entry (SLE) and stay (SLS) were set to ≥ 0.15, and the covariates including age, sex, body weight, body height, stone size, stone position, operation time, stent length (22 cm, 24 cm or 26 cm), crossing midline of distal end (yes vs. no), position of proximal end (upper calyx vs. pelvis), curl of distal end (complete vs. incomplete), curl of proximal end (complete vs. incomplete) were considered. GOF measures, such as the percentage of concordant pairs, estimated area under the receiver operating characteristic curve, and the adjusted generalized R 2 , and the GOF tests, including the deviance GOF test and Pearson χ 2 GOF test, were examined to assess the GOF of each fitted logistic regression model.
Results
The demographic and stent-related characteristics of the 59 patients are listed in Table 1 . There were 22 male (37.3%) and 37 (62.7%) female subjects. The mean age was 53.7 ± 12.9 years. The mean body height and weight were 161.9 ± 7.9 cm (range, 145.9-178 cm) and 66.1 ± 13.3 kg (range, 54-95 kg), respectively. The stone was located in the right ureter in 35 (59.3%) patients and in the left ureter in 24 (40.7%). The mean stone size was 93.1 ± 39.5 mm 2 , and mean operation time was 40.6 minutes.
The frequency distribution of double-J-related symptoms is shown in Table 2 . The incidence of Multivariate analysis of the risk factors associated with each of the five lower urinary tract symptoms (frequency, urgency, urge incontinence, nocturia, and hematuria) in 59 patients is shown in Table 3 . The 26-cm stent was independently associated with the severity of frequency, urgency and nocturia symptoms. The corresponding estimated odds ratios (ORs) were 4.638 [95% confidence interval (CI) = 1.59-13.53; p = 0.0050)] 
Discussion
Placement of a double-J ureteral stent has been widely used in urological surgery since it was first described by Zimskind in 1967.
14 Although it ensures urinary drainage, significant morbidity is associated with the placement of a ureteral stent. Joshi et al reported on the adverse effects of double-J stents, and have suggested that 80% of patients experience bothersome urinary symptoms and pain related to the stent. 1,2 Our results showed a similar prevalence. Stent-related urinary symptoms were thought to have been due to bladder irritation by the stent. Several studies have investigated associated factors that might cause urinary symptoms, but the results remain controversial. 4, 5, [7] [8] [9] [10] [11] [12] [13] 15, 16 El-Nahas et al an analysis of factors responsible for ureteral-stent-associated discomfort. They enrolled patients with various diagnoses and treatment procedures. In addition, they coded symptoms by recording whether symptoms were present or not, which did not represent the exact severity of stent-related symptoms. They used a logistic regression model for multivariate analysis and have concluded that the proper position of the stent coils and shorter stenting duration decrease patient discomfort. 16 We have demonstrated previously that stent length is associated with the position of the distal loop and the related urinary symptoms in a retrospective research, without analyzing perioperative factors. 13 In the present study, we prospectively recruited patients who underwent URSL, and analyzed all possible variables by the proportional odds logistic regression model to determine the factors that were significantly associated with stent-related symptoms. Basic model-fitting techniques for (1) variable selection, (2) GOF assessment, and (3) regression diagnostics were used in our regression analysis to ensure the quality of the results.
It is reasonable to postulate that an overlong stent with a longer intravesical segment might cause more irritation of the bladder, and consequently increase the severity of discomfort. A few previous studies have demonstrated results that are consistent with ours. Rane et al reported that stents crossing the midline of the bladder or those with incomplete loops at the lower end significantly increase morbidity. They have concluded that proper stent length and placement appropriate to each patient's ureteral length are necessary to improve comfort. 9 Liatsikos et al also compared the symptoms associated with placement of the proximal curl in the upper pole and renal pelvis. They have proposed that positioning of the proximal end of the double-J stent in the upper pole of the kidney appears to be better tolerated by patients than is standard insertion in the renal pelvis, in terms of urgency, dysuria and quality of life. 8 and193 cm, and 26-cm stents for patients taller than 193 cm. The main criticism of their study is that subjective symptom scores were not determined. Our results also indicated that the 22-cm stent was appropriate for the study objects whose mean body height was 161.9 cm (range, 145.9-178.0 cm). In addition, subjects treated with 22-cm stent experienced less stent-related symptoms compared with those treated with 24-and 26-cm stent. The present study prospectively analyzed all clinically available parameters by multivariate analysis to establish the predictive factors for stentrelated symptoms after uncomplicated URSL. A small number of patients and the non-randomized design were the major limitations of the study. However, our results provide useful information for endourologists who are choosing an appropriate double-J stent after uncomplicated URSL.
In conclusion, the length of stent and midline crossing had a significant effect on stent-related urinary symptoms during stenting after uncomplicated URSL. The choice of an appropriate length of stent might be the most important issue that we should consider to reduce the severity of stentrelated symptoms.
